scispace - formally typeset
E

Emanuela Marchesini

Researcher at University of Perugia

Publications -  35
Citations -  888

Emanuela Marchesini is an academic researcher from University of Perugia. The author has contributed to research in topics: Haemophilia & Clotting factor. The author has an hindex of 14, co-authored 32 publications receiving 756 citations. Previous affiliations of Emanuela Marchesini include Misericordia University.

Papers
More filters
Journal ArticleDOI

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review.

Alfonso Iorio, +18 more
- 01 Jun 2010 - 
TL;DR: The need for randomized controlled trials to address whether or not the risk of inhibitor in PUPs with hemophilia A differs between rFV III and pdFVIII is underscored.
Journal ArticleDOI

Clotting factor concentrates given to prevent bleeding and bleeding‐related complications in people with hemophilia A or B

Alfonso Iorio, +4 more
- 07 Sep 2011 - 
TL;DR: There is strong evidence from randomised controlled trials and observational trials that prophylaxis preserves joint function in children with hemophilia as compared to on-demand treatment and well-designed randomisedcontrolled trials and prospective observational controlled studies are needed to establish the best proPHylactic regimen.
Journal ArticleDOI

Gender-differences in disease distribution and outcome in hospitalized elderly: data from the REPOSI study.

Salvatore Corrao, +313 more
- 01 Sep 2014 - 
TL;DR: The study showed a gender dimorphism in the demographic and morbidity profiles of hospitalized elderly people, emphasizing once more the need for a personalized process of healthcare.
Journal ArticleDOI

Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study

Marco Proietti, +332 more
- 31 May 2016 - 
TL;DR: Non-adherence to guidelines is highly prevalent among elderly AF patients, despite guideline-adherent treatment being independently associated with lower risk of all-cause and CV deaths.
Journal ArticleDOI

IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII

Davide Matino, +31 more
- 01 Oct 2015 - 
TL;DR: The association between IDO1 competence and inhibitor status is investigated by evaluating hemophilia A patients harboring F8-null mutations and it is determined that defective TLR9-mediated activation of IDO 1 induction is associated with an inhibitor-positive status.